William Blair analyst Brandon Vazquez has maintained their bullish stance on GKOS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors, primarily highlighting the strong performance of Glaukos’s iDose product. The company’s second-quarter sales exceeded expectations by 8%, largely attributed to the success of iDose, which showed significant growth in both the number of accounts and usage within those accounts. This robust performance suggests that Glaukos is at the beginning of a promising revenue increase, with further potential gains anticipated as the company expects another reimbursement win soon.
Despite some challenges, such as ongoing weakness in the U.S. glaucoma segment and a slowdown in international markets, Vazquez remains optimistic. The anticipated launch of Epioxa, pending positive regulatory outcomes, could disrupt the U.S. corneal market in the fourth quarter, but the increasing contribution from iDose is expected to offset these issues. With shares trading at a favorable multiple of projected 2026 sales, Vazquez believes the company’s growth trajectory, driven by iDose and other pipeline products, presents a compelling investment opportunity.
According to TipRanks, Vazquez is an analyst with an average return of -0.6% and a 33.33% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Neogen, Elanco Animal Health, and PROCEPT BioRobotics.
In another report released today, Needham also reiterated a Buy rating on the stock with a $115.00 price target.